These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29269269)

  • 1. Deep Convolutional Neural Network Analysis of Flow Imaging Microscopy Data to Classify Subvisible Particles in Protein Formulations.
    Calderon CP; Daniels AL; Randolph TW
    J Pharm Sci; 2018 Apr; 107(4):999-1008. PubMed ID: 29269269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing Precision Limits of Neural Network-Based Quality Control Metrics in High-Throughput Digital Microscopy.
    Calderon CP; Ripple DC; Srinivasan C; Ma Y; Carrier MJ; Randolph TW; O'Connor TF
    Pharm Res; 2022 Feb; 39(2):263-279. PubMed ID: 35080706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Features in Backgrounds of Microscopy Images Introduce Biases in Machine Learning Analyses.
    Greenblott DN; Johann F; Snell JR; Gieseler H; Calderon CP; Randolph TW
    J Pharm Sci; 2024 May; 113(5):1177-1189. PubMed ID: 38484874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Image Classification of Degraded Polysorbate, Protein and Silicone Oil Sub-Visible Particles Detected by Flow-Imaging Microscopy in Biopharmaceuticals Using a Convolutional Neural Network Model.
    Fedorowicz FM; Chalus P; Kirschenbühler K; Drewes S; Koulov A
    J Pharm Sci; 2023 Dec; 112(12):3099-3108. PubMed ID: 37422283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning approaches to root cause analysis, characterization, and monitoring of subvisible particles in monoclonal antibody formulations.
    Greenblott DN; Zhang J; Calderon CP; Randolph TW
    Biotechnol Bioeng; 2022 Dec; 119(12):3596-3611. PubMed ID: 36124935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of Three Flow Imaging Microscopy Instruments for Image Analysis in Evaluating four Types of Subvisible Particle in Biopharmaceuticals.
    Nishiumi H; Deiringer N; Krause N; Yoneda S; Torisu T; Menzen T; Friess W; Uchiyama S
    J Pharm Sci; 2022 Nov; 111(11):3017-3028. PubMed ID: 35948157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic Investigation on Grinding-Induced Subvisible Particle Formation during Mixing and Filling of Monoclonal Antibody Formulations.
    Gikanga B; Hui A; Maa YF
    PDA J Pharm Sci Technol; 2018; 72(2):117-133. PubMed ID: 29030532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a Self-Supervised Machine Learning Method for Screening of Particulate Samples: A Case Study in Liquid Formulations.
    Salami H; Wang S; Skomski D
    J Pharm Sci; 2023 Mar; 112(3):771-778. PubMed ID: 36240862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow Microscopy Imaging Is Sensitive to Characteristics of Subvisible Particles in Peginesatide Formulations Associated With Severe Adverse Reactions.
    Daniels AL; Randolph TW
    J Pharm Sci; 2018 May; 107(5):1313-1321. PubMed ID: 29409840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Convolutional Neural Networks Enable Highly Accurate and Automated Subvisible Particulate Classification of Biopharmaceuticals.
    Wang S; Liaw A; Chen YM; Su Y; Skomski D
    Pharm Res; 2023 Jun; 40(6):1447-1457. PubMed ID: 36471026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Particulate impurities in cell-based medicinal products traced by flow imaging microscopy combined with deep learning for image analysis.
    Grabarek AD; Senel E; Menzen T; Hoogendoorn KH; Pike-Overzet K; Hawe A; Jiskoot W
    Cytotherapy; 2021 Apr; 23(4):339-347. PubMed ID: 32507606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microflow Imaging Analyses Reflect Mechanisms of Aggregate Formation: Comparing Protein Particle Data Sets Using the Kullback-Leibler Divergence.
    Maddux NR; Daniels AL; Randolph TW
    J Pharm Sci; 2017 May; 106(5):1239-1248. PubMed ID: 28159641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Inherent Particles and Mechanism of Thermal Stress Induced Particle Formation in HSV-2 Viral Vaccine Candidate.
    Li L; Kirkitadze M; Bhandal K; Roque C; Yang E; Carpick B; Rahman N
    Curr Pharm Biotechnol; 2017 Nov; 18(8):638-647. PubMed ID: 28914197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep learning image analysis models pretrained on daily objects are useful for the preliminary characterization of particulate pharmaceutical samples.
    Salami H; Wood C; Ouyang H; Zhao X; Skomski D
    Biotechnol Bioeng; 2023 Aug; 120(8):2175-2185. PubMed ID: 37435969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oil-Immersion Flow Imaging Microscopy for Quantification and Morphological Characterization of Submicron Particles in Biopharmaceuticals.
    Krause N; Kuhn S; Frotscher E; Nikels F; Hawe A; Garidel P; Menzen T
    AAPS J; 2021 Jan; 23(1):13. PubMed ID: 33398482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Label-free flow cytometry analysis of subvisible aggregates in liquid IgG1 antibody formulations.
    Nishi H; Mathäs R; Fürst R; Winter G
    J Pharm Sci; 2014 Jan; 103(1):90-9. PubMed ID: 24218205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel biomedical image indexing and retrieval system via deep preference learning.
    Pang S; Orgun MA; Yu Z
    Comput Methods Programs Biomed; 2018 May; 158():53-69. PubMed ID: 29544790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of Infrared Microscopy to Assess Secondary Structure of Insulin Molecules Within Individual Subvisible Particles in Aqueous Formulations.
    Schack MM; Møller EH; Friderichsen AV; Carpenter JF; Rades T; Groenning M
    J Pharm Sci; 2019 Mar; 108(3):1117-1129. PubMed ID: 30773199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress.
    Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subvisible (2-100 μm) Particle Analysis During Biotherapeutic Drug Product Development: Part 1, Considerations and Strategy.
    Narhi LO; Corvari V; Ripple DC; Afonina N; Cecchini I; Defelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Spitznagel TM; Weiskopf A; Wuchner K
    J Pharm Sci; 2015 Jun; 104(6):1899-1908. PubMed ID: 25832583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.